Emerging therapeutic strategies to enhance HDL function

Lipids in Health and Disease

Volumn 10, Issue , 2011, Pages

  Redondo, Santiago ^a,b   Martínez González, José ^c   Urraca, Concha ^a   Tejerina, Teresa ^a  

^a SCHOOL OF MEDICINE   (Spain)

^b HOSPITAL NUESTRA SEÑORA DE SONSOLES   (Spain)

^c Institut Català de Ciències Cardiovasculars   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANACETRAPIB; ATORVASTATIN; CHOLESTEROL ESTER TRANSFER PROTEIN; DALCETRAPIB; ETC 216; HIGH DENSITY LIPOPROTEIN; APOLIPOPROTEIN A I MILANO; APOLIPOPROTEIN A-I MILANO; APOLIPOPROTEIN A1; CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; LIVER X RECEPTOR; NEW DRUG; ORPHAN NUCLEAR RECEPTOR; SCARB1 PROTEIN, HUMAN; SCAVENGER RECEPTOR B;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHOLESTEROL TRANSPORT; DRUG STRUCTURE; HUMAN; LIVER; NONHUMAN; REVIEW; ANIMAL; ATHEROSCLEROTIC PLAQUE; BLOOD; DRUG ANTAGONISM; DRUG POTENTIATION; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY;

ANIMALS; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEIN A-I; CARDIOVASCULAR DISEASES; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEINS; DRUGS, INVESTIGATIONAL; HUMANS; LIPOPROTEINS, HDL; MOLECULAR TARGETED THERAPY; ORPHAN NUCLEAR RECEPTORS; PLAQUE, ATHEROSCLEROTIC; SCAVENGER RECEPTORS, CLASS B;

EID: 80053615792     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-10-175     Document Type: Review

References (59)

1. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, Jacobs DR Jr, Bangdiwala S, Tyroler HA, Circulation 1989 79 8 15 10.1161/01.CIR.79.1.8 2642759 (Pubitemid 19043669)
2. Seeking novel targets for improving in vivo macrophage-specific reverse cholesterol transport: translating basic science into new therapies for the prevention and treatment of atherosclerosis. Julve J, Llaverias G, Blanco-Vaca F, Escol-Gil JC, Curr Vasc Pharmacol 2011 9 220 237 10.2174/157016111794519264 21143175
3. Cholesterol transport between cells and body fluids. Role of plasma lipoproteins and the plasma cholesterol esterification system. Fielding CJ, Fielding PE, Med Clin North Am 1982 66 363 373 7040842 (Pubitemid 12115371)
4. Pathways by which reconstituted high-density lipoprotein mobilizes free cholesterol from whole body and from macrophages. Cuchel M, Lund-Katz S, de la Llera-Moya M, Millar JS, Chang D, Fuki I, Rothblat GH, Phillips MC, Rader DJ, Arterioscler Thromb Vasc Biol 2010 30 526 532
5. High density lipoprotein plasma fractions inhibit aortic fatty streaks in cholesterol-fed rabbits. Badimon JJ, Badimon L, Galvez A, Dische R, Fuster V, Lab Invest 1989 60 455 461 2927083 (Pubitemid 19095962)
6. Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. Badimon JJ, Badimon L, Fuster V, J Clin Invest 1990 85 1234 1241 10.1172/JCI114558 2318976 (Pubitemid 20123768)
7. Rapid change in plaque size, composition, and molecular footprint after recombinant apolipoprotein A-I Milano (ETC-216) administration: magnetic resonance imaging study in an experimental model of atherosclerosis. Ibãez B, Vilahur G, Cimmino G, Speidl WS, Pinero A, Choi BG, Zafar MU, Santos-Gallego CG, Krause B, Badimon L, Fuster V, Badimon JJ, J Am Coll Cardiol 2008 51 1104 1109 10.1016/j.jacc.2007.09.071 18342230 (Pubitemid 351374767)
8. Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study. Lee JM, Robson MD, Yu LM, Shirodaria CC, Cunnington C, Kylintireas I, Digby JE, Bannister T, Handa A, Wiesmann F, Durrington PN, Channon KM, Neubauer S, Choudhury RP, J Am Coll Cardiol 2009 54 1787 1794 10.1016/j.jacc.2009.06.036 19874992
9. Determinants of plasma HDL concentrations and reverse cholesterol transport. Lewis GF, Curr Opin Cardiol 2006 21 345 352 10.1097/01.hco. 0000231405.76930.a0 16755204 (Pubitemid 44315068)
10. Atheroprotective effects of high-density lipoproteins. Assmann G, Nofer JR, Annu Rev Med 2003 54 321 341 10.1146/annurev.med.54.101601.152409 12414916 (Pubitemid 37386400)
11. Antiinflammatory properties of HDL. Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab M, Fogelman AM, Circ Res 2004 95 764 772 10.1161/01.RES.0000146094.59640.13 15486323 (Pubitemid 39390578)
12. HDL/apolipoprotein A-I binds to macrophage-derived progranulin and suppresses its conversion into proinflammatory granulins. Okura H, Yamashita S, Ohama T, Saga A, Yamamoto-Kakuta A, Hamada Y, Sougawa N, Ohyama R, Sawa Y, Matsuyama A, J Atheroscler Thromb 2010 17 568 577 10.5551/jat.3921 20215705
13. Effect of high-density lipoproteins on the expression of adhesion molecules in endothelial cells. Barter PJ, Baker PW, Rye KA, Curr Opin Lipidol 2002 13 285 288 10.1097/00041433-200206000-00008 12045398 (Pubitemid 34592285)
14. High density lipoprotein-associated lysosphingolipids reduce E-selectin expression in human endothelial cells. Nofer JR, Geigenmüller S, Göpfert C, Assmann G, Buddecke E, Schmidt A, Biochem Biophys Res Commun 2003 310 98 103 10.1016/j.bbrc.2003.08.126 14511654 (Pubitemid 37162768)
15. HDL-associated PAF-AH reduces endothelial adhesiveness in apoE-/- mice. Theilmeier G, De Geest B, Van Veldhoven PP, Stengel D, Michiels C, Lox M, Landeloos M, Chapman MJ, Ninio E, Collen D, Himpens B, Holvoet P, FASEB J 2000 14 2032 2039 10.1096/fj.99-1029com 11023987
16. Low dose apolipoprotein A-I rescues carotid arteries from inflammation in vivo. Puranik R, Bao S, Nobecourt E, Nicholls SJ, Dusting GJ, Barter PJ, Celermajer DS, Rye KA, Atherosclerosis 2008 196 240 247 10.1016/j. atherosclerosis.2007.05.008 17586510
17. Decreased high-density lipoprotein cholesterol level is an independent correlate of circulating tumor necrosis factor-alpha in a general population. Yamagishi S, Adachi H, Matsui T, Nakamura K, Enomoto M, Fukami A, Otsuka M, Kumagae S, Nanjo Y, Imaizumi T, Clin Cardiol 2009 32 29 E32 19816991
18. High density lipoprotein is the major carrier of lipid hydroperoxides in human blood plasma from fasting donors. Bowry VW, Stanley KK, Stocker R, Proc Natl Acad Sci USA 1992 89 10316 10320 10.1073/pnas.89.21.10316 1332045
19. Anti-oxidant properties of high-density lipoprotein and atherosclerosis. Podrez EA, Clin Exp Pharmacol Physiol 2010 37 719 725 10.1111/j.1440-1681.2010. 05380.x 20374263
20. Reconstituted high-density lipoprotein inhibits thrombin-induced endothelial tissue factor expression through inhibition of RhoA and stimulation of phosphatidylinositol 3-kinase but not Akt/endothelial nitric oxide synthase. Viswambharan H, Ming XF, Zhu S, Hubsch A, Lerch P, Vergères G, Rusconi S, Yang Z, Circ Res 2004 94 918 925 10.1161/01.RES.0000124302.20396.B7 14988229 (Pubitemid 38490069)
21. High-density lipoproteins, platelets and the pathogenesis of atherosclerosis. Nofer JR, Brodde MF, Kehrel BE, Clin Exp Pharmacol Physiol 2010 37 726 735 10.1111/j.1440-1681.2010.05377.x 20337657
22. High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C. Griffin JH, Kojima K, Banka CL, Curtiss LK, Fernández JA, J Clin Invest 1999 103 219 227 10.1172/JCI5006 9916134 (Pubitemid 29053140)
23. Sphingosine-1-phosphate: A bioactive lipid that confers high-density lipoprotein with vasculoprotection mediated by nitric oxide and prostacyclin. Rodríguez C, González-Díez M, Badimon L, Martínez-González J, Thromb Haemost 2009 101 665 673 19350109
24. High density lipoprotein prevents oxidized low density lipoprotein-induced inhibition of endothelial nitric-oxide synthase localization and activation in caveolae. Uittenbogaard A, Shaul PW, Yuhanna IS, Blair A, Smart EJ, J Biol Chem 2000 275 11278 11283 10.1074/jbc.275.15.11278 10753938 (Pubitemid 30212775)
25. High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase. Yuhanna IS, Zhu Y, Cox BE, Hahner LD, Osborne-Lawrence S, Lu P, Marcel YL, Anderson RG, Mendelsohn ME, Hobbs HH, Shaul PW, Nat Med 2001 7 853 857 10.1038/89986 11433352 (Pubitemid 32691642)
26. A-IMilano apoprotein. Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family. Franceschini G, Sirtori CR, Capurso A, Weisgraber KH, Mahley RW, J Clin Invest 1980 66 892 900 10.1172/JCI109956 7430351 (Pubitemid 11233787)
27. Isolation and characterization of a cysteine-containing variant of the apoprotein A-1 from high density lipoprotein. Weisgraber KH, Bersot TP, Mahley RW, Franceschini G, Magani D, Sirtori CR, J Clin Invest 1980 66 901 907 10.1172/JCI109957 6776144 (Pubitemid 11233788)
28. Up-regulation of reverse cholesterol transport key players and rescue from global inflammation by ApoA-I(Milano). Cimmino G, Ibanez B, Vilahur G, Speidl WS, Fuster V, Badimon L, Badimon JJ, J Cell Mol Med 2009 13 3226 3235 10.1111/j.1582-4934.2008.00614.x 19120689
29. Macrophage reverse cholesterol transport in mice expressing ApoA-I Milano. Alexander ET, Weibel GL, Joshi MR, Vedhachalam C, de la Llera-Moya M, Rothblat GH, Phillips MC, Rader DJ, Arterioscler Thromb Vasc Biol 2009 29 1496 501 10.1161/ATVBAHA.109.191379 19661486
30. Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. Zhong S, Sharp DS, Grove JS, Bruce C, Yano K, Curb JD, Tall AR, J Clin Invest 1996 97 2917 2923 10.1172/JCI118751 8675707 (Pubitemid 26197108)
31. HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE- and ABCG1-dependent pathway. Matsuura F, Wang N, Chen W, Jiang XC, Tall AR, J Clin Invest 2006 116 1435 1342 10.1172/JCI27602 16670775
32. Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors. Chapman MJ, Le Goff W, Guerin M, Kontush A, Eur Heart J 2010 31 149 164 10.1093/eurheartj/ehp399 19825813
33. Association of circulating cholesteryl ester transfer protein activity with incidence of cardiovascular disease in the community. Vasan RS, Pencina MJ, Robins SJ, Zachariah JP, Kaur G, D'Agostino RB, Ordovas JM, Circulation 2009 120 2414 2420 10.1161/CIRCULATIONAHA.109.872705 19948972
34. High density lipoproteins with differing apolipoproteins: relationships to postprandial lipemia, cholesteryl ester transfer protein, and activities of lipoprotein lipase, hepatic lipase, and lecithin: cholesterol acyltransferase. Mowri HO, Patsch JR, Ritsch A, Föger B, Brown S, Patsch W, J Lipid Res 1994 35 291 300 8169533 (Pubitemid 24050442)
35. ETC-216 for coronary artery disease. Nicholls SJ, Uno K, Kataoka Y, Nissen SE, Expert Opin Biol Ther 2011 11 387 394 10.1517/14712598.2011.557061 21271950
36. Relationship between atheroma regression and change in lumen size after infusion of apolipoprotein A-I Milano. Nicholls SJ, Tuzcu EM, Sipahi I, Schoenhagen P, Crowe T, Kapadia S, Niossen SE, J Am Coll Cardiol 2006 47 992 997 10.1016/j.jacc.2005.11.040 16516083
37. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, Eaton GM, Lauer MA, Sheldon WS, Grines CL, Halpern S, Crowe T, Blankenship JC, Kerensky R, JAMA 2003 290 2292 2300 10.1001/jama.290.17.2292 14600188 (Pubitemid 37430562)
38. Oral administration of an Apo A-I mimetic Peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Navab M, Anantharamaiah GM, Hama S, Garber DW, Chaddha M, Hough G, Lallone R, Fogelman AM, Circulation 2002 105 290 292 10.1161/hc0302.103711 11804981 (Pubitemid 34106174)
39. Wild-type ApoA-I and the Milano variant have similar abilities to stimulate cellular lipid mobilization and efflux. Weibel GL, Alexander ET, Joshi MR, Rader DJ, Lund-Katz S, Phillips MC, Rothblat GH, Arterioscler Thromb Vasc Biol 2007 27 2022 2029 10.1161/ATVBAHA.107.148403 17615385 (Pubitemid 47312313)
40. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. Tardif JC, Grégoire J, L'Allier PL, Ibrahim R, Lespérance J, Heinonen TM, Kouz S, Berry C, Basser R, Lavoie MA, Guertin MC, Rodés-Cabau J, Effect of rHDL on Atherosclerosis-Safety and Efficacy (ERASE) Investigators, JAMA 2007 297 1675 1682 10.1001/jama.297.15.jpc70004 17387133 (Pubitemid 46631626)
41. Infusion of reconstituted high-density lipoprotein leads to acute changes in human atherosclerotic plaque. Shaw JA, Bobik A, Murphy A, Kanellakis P, Blombery P, Mukhamedova N, Woollard K, Lyon S, Sviridov D, Dart AM, Circ Res 2008 103 1084 1091 10.1161/CIRCRESAHA.108.182063 18832751
42. Effect of torcetrapib on the progression of coronary atherosclerosis. Nissen SE, Tardif JC, Nicholls SJ, Revkin JH, Shear CL, Duggan WT, Ruzyllo W, Bachinsky WB, Lasala GP, Tuzcu EM, ILLUSTRATE Investigators, N Engl J Med 2007 356 1304 1316 10.1056/NEJMoa070635 17387129 (Pubitemid 46513296)
43. Effects of torcetrapib in patients at high risk for coronary events. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B, ILLUMINATE Investigators, N Engl J Med 2007 357 2109 2122 10.1056/NEJMoa0706628 17984165 (Pubitemid 350146106)
44. Surrogate end points and FDA approval: a tale of 2 lipid-altering drugs. Psaty BM, Lumley T, JAMA 2008 299 1474 1476 10.1001/jama.299.12.1474 18364491 (Pubitemid 351468448)
45. Torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein inhibition. Hu X, Dietz JD, Xia C, Knight DR, Loging WT, Smith AH, Yuan H, Perry DA, Keiser J, Endocrinology 2009 150 2211 2219 19164467
46. Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial. Stein EA, Roth EM, Rhyne JM, Burgess T, Kallend D, Robinson JG, Eur Heart J 2010 31 480 488 10.1093/eurheartj/ehp601 20097702
47. Safety of anacetrapib in patients with or at high risk for coronary heart disease. Cannon CP, Shah S, Dansky HM, Davidson M, Brinton EA, Gotto AM, Stepanavage M, Liu SX, Gibbons P, Ashraf TB, Zafarino J, Mitchel Y, Barter P, Determining the Efficacy and Tolerability Investigators: Determining the Efficacy and Tolerability Investigators, N Engl J Med 2010 363 2406 2415 10.1056/NEJMoa1009744 21082868
48. Dalcetrapib: no off-target toxicity on blood pressure or on genes related to the renin-angiotensin-aldosterone system in rats. Stroes ES, Kastelein JJ, Bénardeau A, Kuhlmann O, Blum D, Campos LA, Clerc RG, Nisor EJ, Br J Pharmacol 2009 158 1763 1770 10.1111/j.1476-5381.2009.00460.x 19917065
49. Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia. Kuivenhoven JA, de Grooth GJ, Kawamura H, Klerkx AH, Wilhelm F, Trip MD, Katelein JJ, Am J Cardiol 2005 95 1085 1088 10.1016/j.amjcard.2004.12.064 15842977 (Pubitemid 40544314)
50. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies. Krishna R, Anderson MS, Bergman AJ, Jin B, Fallon M, Cote J, Rosko K, Chavez-Eng C, Lutz R, Bloomfield DM, Gutierrez M, Doherty J, Bieberdorf F, Chodakewitz J, Gottesdiener KM, Wagner JA, Lancet 2007 370 1907 1914 10.1016/S0140-6736(07)61813-3 18068514 (Pubitemid 350192656)
51. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients. Bloomfield D, Carlson GL, Sapre A, Tribble D, McKenney JM, Littlejohn TW, Sisk CM, Mitchel Y, Pasternak RC, Am Heart J 2009 157 352 360 10.1016/j.ahj.2008.09.022 19185645
52. Decoding transcriptional programs regulated by PPARs and LXRs in the macrophage: effects on lipid homeostasis, inflammation, and atherosclerosis. Ricote M, Valledor AF, Glass CK, Arterioscler Thromb Vasc Biol 2004 24 230 239 14592855 (Pubitemid 38202188)
53. Stimulation of cholesterol excretion by the liver × receptor agonist requires ATP-binding cassette transporters G5 and G8. Yu L, York J, von Bergmann K, Lutjohann D, Cohen JC, Hobbs HH, J Biol Chem 2003 278 15565 15570 10.1074/jbc.M301311200 12601003 (Pubitemid 36799664)
54. Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXR alpha. Venkateswaran A, Laffitte BA, Joseph SB, Mak PA, Wilpitz DC, Edwards PA, Tontonoz P, Proc Natl Acad Sci USA 2000 97 12097 12102 10.1073/pnas. 200367697 11035776
55. Pharmacological activation of liver × receptors promotes reverse cholesterol transport in vivo. Naik SU, Wang X, Da Silva JS, Jaye M, Macphee CH, Reilly MP, Billheimer JT, Rothblat GH, Rader DJ, Circulation 2006 113 90 97 16365197 (Pubitemid 43958493)
56. A novel potent synthetic steroidal liver × receptor agonist lowers plasma cholesterol and triglycerides and reduces atherosclerosis in LDLR(-/-) mice. Peng D, Hiipakka RA, Xie JT, Dai Q, Kokontis JM, Reardon CA, Getz GS, Liao S, Br J Pharmacol 2011 162 1792 1804 10.1111/j.1476-5381.2011.01202.x 21232031
57. The liver × receptor (LXR) and hepatic lipogenesis. The carbohydrate-response element-binding protein is a target gene of LXR. Cha JY, Repa JJ, J Biol Chem 2007 282 743 751 17107947 (Pubitemid 47076632)
58. Loss of SR-BI expression leads to the early onset of occlusive atherosclerotic coronary artery disease, spontaneous myocardial infarctions, severe cardiac dysfunction, and premature death in apolipoprotein E-deficient mice. Braun A, Trigatti BL, Post MJ, Sato K, Simons M, Edelberg JM, Rosenberg RD, Schrenzel M, Krieger M, Circ Res 2002 90 270 276 10.1161/hh0302.104462 11861414 (Pubitemid 34633927)
59. Increased HDL cholesterol and apoA-I in humans and mice treated with a novel SR-BI inhibitor. Masson D, Koseki M, Ishibashi M, Larson CJ, Miller SG, King BD, Tall AR, Arterioscler Thromb Vasc Biol 2009 29 2054 2060 10.1161/ATVBAHA.109.191320 19815817